Teprotumumab: a review in thyroid eye disease
T Nie, YN Lamb - Drugs, 2022 - Springer
Teprotumumab (TEPEZZA®), a monoclonal antibody that inhibits the insulin-like growth
factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment …
factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment …
Dysthyroid Optic Neuropathy
ARGG Potvin, F Pakdel, P Saeed - Ophthalmic Plastic & …, 2023 - journals.lww.com
Purpose: Dysthyroid optic neuropathy (DON) is a sight-threatening complication of thyroid
eye disease (TED). This review provides an overview of the epidemiology, pathogenesis …
eye disease (TED). This review provides an overview of the epidemiology, pathogenesis …
Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease
PS Subramanian, RI Cho, A Kahana - Current opinion in …, 2023 - journals.lww.com
Efficacy of teprotumumab therapy in patients with long-durat... : Current Opinion in
Ophthalmology Efficacy of teprotumumab therapy in patients with long-duration thyroid eye …
Ophthalmology Efficacy of teprotumumab therapy in patients with long-duration thyroid eye …
Fibrocyte participation in thyroid-associated ophthalmopathy suggests new approaches to therapy
TJ Smith - Ophthalmic Plastic & Reconstructive Surgery, 2023 - journals.lww.com
Purpose: Review the historical context of research and changing therapeutic landscape of
thyroid-associated ophthalmopathy (TAO) by focusing on the relationship between TAO …
thyroid-associated ophthalmopathy (TAO) by focusing on the relationship between TAO …
The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
F Lin, Q Yao, B Yu, Z Deng, J Qiu… - International Journal of …, 2023 - Wiley Online Library
In this study, we conducted a meta‐analysis to assess the efficacy and safety of
teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed …
teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed …
An unusual mimic of intracranial hypertension
N Ghane, JC Kattah, B Mannett, SH Hong - Practical Neurology, 2024 - pn.bmj.com
A 60-year-old man had a 2-week history of daily recurrent episodes of transient, painless
vision loss, each lasting 3–5 s. He had attended ophthalmology for years because of …
vision loss, each lasting 3–5 s. He had attended ophthalmology for years because of …
Advances in immune-targeted therapy for Graves' ophthalmopathy.
W Lv, Y Fu - Journal of Chinese Pharmaceutical Sciences, 2023 - search.ebscohost.com
Graves' ophthalmopathy (GO) is an autoimmune disease characterized by lymphocytic
infiltration behind the eyes. The pathogenesis of this disease is complex, and although no …
infiltration behind the eyes. The pathogenesis of this disease is complex, and although no …
Literature Commentary
D Jons, I Kmezic, C Lindberg, J Lindh, F Lundin… - journals.lww.com
Literature Commentary : Journal of Neuro-Ophthalmology Literature Commentary : Journal
of Neuro-Ophthalmology Log in or Register Subscribe to journalSubscribe Get new issue …
of Neuro-Ophthalmology Log in or Register Subscribe to journalSubscribe Get new issue …
[引用][C] Teprotumumab dans le traitement de l'orbitopathie dysthyroidienne: le Saint-Graal, vraiment?
A Martel - Journal Français d'Ophtalmologie, 2023 - Elsevier